CIP2A shRNA Plasmid (h) from Santa Cruz Biotechnology, Inc. | Biocompare.com

Supplier Images

CIP2A shRNA Plasmid (h)

Be the first to write a review!

Citations:

Supplier Page from
Santa Cruz Biotechnology, Inc. for
CIP2A shRNA Plasmid (h)

Product Specs
ItemCIP2A shRNA Plasmid (h)
CompanySanta Cruz Biotechnology, Inc.
Price $592.00Supplier Page View Company Product Page
Catalog Numbersc-77964-SH
Quantity20 µg
RNA TypeshRNA Clones
Vector Type (Standardized)Lentiviral
NCBI Gene AliasesKIAA1524, NOCIVA, p90
NCBI Full Gene Namecellular inhibitor of PP2A
Specieshuman
TypeshRNA Plasmid

Add to Compare List

Santa Cruz Biotechnology, Inc.

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) The role of CIP2A as a therapeutic target of rapamycin in radioresistant head and neck cancer with TP53 mutationHead & neckSeptember 1, 2019Kim SH, Lee WH, Seong D, An JH, Je HU, Nam HY, Kim SY, Kim SW, Han MW.

(2) siRNA-Mediated Silencing of CIP2A Enhances Docetaxel Activity Against PC-3 Prostate Cancer CellsAdvanced pharmaceutical bulletinDecember 1, 2017Razi Soofiyani S, Mohammad Hoseini A, Mohammadi A, Khaze Shahgoli V, Baradaran B, Hejazi MS.

(3) Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cellsOncotargetAugust 29, 2017Zhao M, Howard EW, Parris AB, Guo Z, Zhao Q, Ma Z, Xing Y, Liu B, Edgerton SM, Thor AD, et al.

(4) CIP2A regulates proliferation and apoptosis of multiple myeloma cellsMolecular medicine reportsSeptember 1, 2016Zheng Z, Qiao Z, Chen W, Gong R, Wang Y, Xu L, Ma Y, Zhang L, Lu Y, Jiang B, et al.

(5) CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutationLung cancer (Amsterdam, Netherlands)August 1, 2014Wang CY, Chao TT, Chang FY, Chen YL, Tsai YT, Lin HI, Huang YC, Shiau CW, Yu CJ, Chen KF.

(6) Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progressionBloodJune 16, 2011Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, Clark RE.

Be the First to Write a Review!